Research Pathology
The overall goal of Research Pathology Shared Resources (RP-SR) is to provide COHCCC Members with access to high-quality, timely, and cost-effective pathology services that directly support a broad range of studies and access to human biorepository collections. RP-SR comprises the Solid Tumor Biorepository (STB) and Hematopoietic Tissue Biorepository (HTB), Research-(Histology, Molecular Pathology, & Cytogenetics); and the Research Pathology Informatics (RPI) resource.
The Biorepository Services include procurement of tissue, blood/derivatives from patients and volunteers, bone marrow (BM) aspirates, buccal cells and skin, and stool (for microbiome studies) and normal donor blood collection protocols. the Biorepository Services collect, de-identify, and process tissues for correlative studies from patients enrolled in clinical trials. HTB services include cryopreservation of viable mononuclear cells, immunophenotype-based cell characterization and enrichment, and isolation and expansion of mesenchymal stem/stromal cells with DNA, RNA, and protein extraction. Specimen tracking is via LabVantage (LV) management system. Histopathology services include expert interpretation and categorization for solid and liquid tumors by specialist pathologists and hematopathologists, immunohistochemistry (IHC) validation, multiplex IHC, and whole slide imaging. The Cytogenetics Laboratory provides cell line characterization, chromosomal microarray analyses, FISH analyses performed on suspensions, FFPE including tissue microarrays, and frozen sections. The Research Molecular Pathology Laboratory provides targeted DNA sequencing and data interpretation, gene expression assays, tissue-based digital spatial profiling, circulating tumor cell isolation , digital PCR, and RNA in situ hybridization services. In conjunction with the Honest Broker group, HTB and RP Informatics provide support for annotation and cohort identification for project requests.
Specific Aims for RP-SR:
Aim 1. Provide centralized and standard procurement, processing, storage, annotation, and distribution of human biospecimens and coordinate specimen collection across the COH Clinical Network.
Aim 2. Provide high quality, cost-effective, and value-added research histology in the specialized areas of histopathology, hematopathology, immunohistochemistry, and digital pathology and provide specialized collections and cell enrichment services for COHCCC Members.
Aim 3. Provide tissue-based genomic analysis and cytogenetic services for COHCCC Members.
Members Utilization by %Revenue 2017–21: 87.3 Total (11.2 MCBC, 24.4 DCT, 18.5 CI, 27.3 HM, 6 CCPS)
Publications by Members: 211, 72 with Impact Factor >10
Grants Supported: 158 Total (4 ACS, 8 CIRM, 11 DoD, 3 LLS, 71 NCI of 115 NIH (73 R01, 5 U01))
Using the Facility
- Routine histology services (processing, embedding, staining and special stains)
- More complex histology services (cedar wood oil, tissue microarrays, TUNEL, ISH and antibody optimization)
- Digital imaging
- Immunohistochemistry (IHC), e.g., one to five colors supported. We will have a link to a page to display slides.
- Other histopathology services available (review and grading of slides)
Meet the Team
Leadership
Chair and Professor, Department of Pathology
Full Bio
At City of Hope, Dr. Marcucci is playing a key role in our efforts to further expand and broaden our world-renowned work in leukemia research and treatment.
Raju K. Pillai, M.D., is an assistant clinical professor specializing in hematopathology, molecular pathology and pathology bioinformatics. He is also a member of the Toni Stephenson Lymphoma Center. Dr. Pillai's research interests include molecular pathogenesis of lymphomas and leukemias and the application of panomics technologies in diagnostic pathology.
Zhirong Yin plays a key role in the growth and success of City of Hope's many clinical trials. As a trained pathologist, she provides critical technical and scientific expertise, assisting in the development and validation of research methods.
Core Staff
Karen Miller CLS, MT (ASCP)
Senior Manager
Lucy Ghoda, Ph.D.
HTB Manager
Contact the Team
Our Publications
Ding YC, Wu H, Davicioni E, Karnes RJ, Klein EA, Den RB, Steele L, Neuhausen SL. J Transl Genet Genom. 2021;5:50-61. PMID: 33928239; PMCID: PMC8081383.
Ding YC, Steele L, Warden C, Wilczynski S, Mortimer J, Yuan Y, Neuhausen SL. Oncotarget. 2019;10(2):198-208. PMID: 30719214; PMCID: PMC6349443.
Lindner SE, Egelston CA, Huard SM, Lee PP, Wang LD. Arhgap25 Immunohorizons. 2020;4(5):274-81. PMID: 32434881; PMCID: PMC7301639.
Sampath S, Won H, Massarelli E, Li M, Frankel P, Vora N, Vora L, Maghami E, Kortylewski M. Oncotarget. 2018;9(13):11279-90. PMID: 29541413; PMCID: PMC5834279.
Petrossian K, Kanaya N, Lo C, Hsu PY, Nguyen D, Yang L, Yang L, Warden C, Wu X, Pillai R, Bernal L, Huang CS, Kruper L, Yuan Y, Somlo G, Mortimer J, Chen S. Oncotarget. 2018;9(45):27736-51. PMID: 29963233; PMCID: PMC6021239.
In a given year, City of Hope conducts more than 400 clinical trials enrolling more than 6,000 patients.
City of Hope is focused on basic and clinical research in cancer, diabetes and other life-threatening diseases.